A recent review systematically summarizes the latest advances in tumor microenvironment （TME）-responsive nanomedicines. In addition, it discusses several emerging challenges and prospects for TME-responsive nanomedicines, with the aim of providing novel insights in this field.
Cancer remains one of the most serious public health challenges worldwide. The advent of nanomedicine has opened new avenues for targeted tumor therapy; however, challenges such as inefficient and nonspecific drug release continue to limit therapeutic efficacy. Tumor microenvironment (TME)-responsive nanomedicines offer a promising strategy to address these limitations. In a recent review published in Advanced Cancer Research, the authors summarize the latest advances in TME-responsive nanomedicine over the past few years, and also discuss several emerging challenges and future prospects for these therapies.
TME constitutes a complex ecosystem with pathological characteristics that are markedly different from those of normal tissues. These features are primarily manifested as low pH, elevated levels of glutathione and reactive oxygen species, hypoxia, and overexpression of certain enzymes and adenosine triphosphate. Such endogenous biological signals provide valuable opportunities for the design of TME-responsive nanoplatforms. These smart carriers are capable of maintaining drug stability during systemic circulation, while undergoing specific structural transformations—such as hydrolysis, bond cleavage, charge reversal, or disassembly—upon exposure to particular stimuli within the TME. This enables precise drug release and thereby enhances therapeutic efficacy.
Key highlights include:
A systematic overview of single and multi-TME-responsive nanomedicines designed for tumor-specific drug release.
A critical analysis of the major barriers hindering clinical translation, such as tumor heterogeneity, insufficient drug release, and difficulties in upstream delivery, along with corresponding optimization strategies.
By synthesizing current advances and unmet clinical needs, this review outlines future trends in TME-responsive nanomedicines, offering insights to guide the exploration of nanotechnology in cancer therapy.
Citation： Wang Q, Sun M, Han Y, Li Z, Liu J, et al. Tumor microenvironment responsive nanotherapeutics in cancer treatment: obstacles, opportunities and future prospects. Adv. Cancer Res. 2026(2):0007
https://doi.org/10.55092/acr20260007.
Advanced Cancer Research
Literature review
Not applicable
Tumor microenvironment responsive nanotherapeutics in cancer treatment: obstacles, opportunities and future prospects
30-May-2026